Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

119.55 +0.18 (+0.15%)
Streaming Delayed Price Updated: 12:24 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,111,525
Open 118.95
Bid (Size) 119.54 (100)
Ask (Size) 119.58 (100)
Prev. Close 119.37
Today's Range 118.65 - 120.06
52wk Range 73.31 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
ARM Makes Its Move While Wall Street Watches the Strait ↗
Via Chartmill

Performance

YTD
+12.3%
+12.3%
1 Month
-3.4%
-3.4%
3 Month
+12.3%
+12.3%
6 Month
+50.1%
+50.1%
1 Year
+36.1%
+36.1%

More News

Read More
News headline image
The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind
Via MarketMinute
Topics Artificial Intelligence Economy
Merck & Co. Inc. (NYSE:MRK) Offers a Steady Dividend Backed by Strong Fundamentals ↗
Via Chartmill
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
From Merck & Co., Inc.
Via Business Wire
News headline image
1 S&P 500 Stock to Target This Week and 2 We Ignore
Via StockStory
Topics Stocks
News headline image
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
From Merck & Co., Inc.
Via Business Wire
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
Via MarketMinute
Topics Earnings Economy Initial Public Offering
News headline image
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
From Merck Sharp & Dohme
Via Business Wire
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
From Merck & Co., Inc.
Via Business Wire
News headline image
1 ETF That Could Turn $100 Per Month Into $67,380 ↗
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Avoid
Via StockStory
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
Via MarketMinute
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
Via StockStory
Topics Stocks

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 119.55
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/26/26 12:24 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 302.63B
How many shares of Merck & Co are outstanding?
Merck & Co has 303B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.